The proceeds will fund a Phase 3 test of a medicine once known as buparlisib and tested by Novartis in dozens of trials.Dive Brief:Cancer drug developer Adlai Nortye on Thursday raised $57.5 million in an initial public offering, becoming the 16th biotechnology company to debut on a U.S. stock exchange this year, according to BioPharma […]
